In the context of acute myeloid leukemia (AML) treatment, the interface between chemotherapy and immunotherapy is at present getting closer as never before. Scientific research is oriented in overcoming the main limits of actual chemotherapeutic regimens against AML, which still accounts for a considerable number of relapsed or resistant forms.A lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently gene-modified immune cells have been considered as an alternative approach whenever chemotherapy fails to eradicate the disease. In this sense, AML is a potential suitable target for immunotherapeutic approaches, due to overexpression of several tumor antigens.Here we describe the state of the art of mAbs and cellular therapies employing engineered immune effectors, developed against specific AML antigens, in a window embracing preclinical research and translational studies to the clinical setting. © 2013 Elsevier B.V.

Tettamanti, S., Magnani, C., Biondi, A., Biagi, E. (2013). Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors. IMMUNOLOGY LETTERS, 155(1, 2), 43-46 [10.1016/j.imlet.2013.09.013].

Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors

MAGNANI, CHIARA FRANCESCA;BIONDI, ANDREA;BIAGI, ETTORE
2013

Abstract

In the context of acute myeloid leukemia (AML) treatment, the interface between chemotherapy and immunotherapy is at present getting closer as never before. Scientific research is oriented in overcoming the main limits of actual chemotherapeutic regimens against AML, which still accounts for a considerable number of relapsed or resistant forms.A lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently gene-modified immune cells have been considered as an alternative approach whenever chemotherapy fails to eradicate the disease. In this sense, AML is a potential suitable target for immunotherapeutic approaches, due to overexpression of several tumor antigens.Here we describe the state of the art of mAbs and cellular therapies employing engineered immune effectors, developed against specific AML antigens, in a window embracing preclinical research and translational studies to the clinical setting. © 2013 Elsevier B.V.
Articolo in rivista - Review Essay
AML, cell therapy, monoclonal antibodies, chimeric antigen receptors, gene therapy
English
2013
155
1, 2
43
46
none
Tettamanti, S., Magnani, C., Biondi, A., Biagi, E. (2013). Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors. IMMUNOLOGY LETTERS, 155(1, 2), 43-46 [10.1016/j.imlet.2013.09.013].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/47082
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
Social impact